ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 1742.8 | 1695.4 | 1424.9 |
| Other income | 111.5 | 63.2 | 44.0 |
| Total income | 1854.3 | 1758.5 | 1468.9 |
| Profit before exceptional items & tax | 505.8 | 386.5 | 288.3 |
| Exceptional items | 0.0 | 24.3 | 0.0 |
| Profit before tax | 505.8 | 362.1 | 288.3 |
| Net profit | 366.7 | 261.5 | 186.5 |
| Operating margin | 27.3% | 20.6% | 19.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +96.60% |
|---|---|
| Net profit, quarter on quarter | +40.20% |
| Revenue, year on year | +22.30% |
BSE results filing, NSE: GLAND. Figures extracted from the filing.
Gland Pharma Ltd: key numbers
- Share price
- ₹3,300.50
- Market cap
- ₹54,462 Cr
- Revenue (annual)
- ₹6,431 Cr
- Net profit (annual)
- ₹1,027 Cr
- P/E (TTM)
- 44.1×Sector 43.8×
- Promoter holding
- 45.75%-6.02% QoQ
- FII holding
- 10.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gland Pharma Ltd
All →Gland Pharma Annual General Meeting
Gland Pharma's shareholders approved the appointment of Xingli Wang as Non-Executive Non-Independent Director via postal ballot. The ordinary resolution passed with 97.07% of votes in favour.
Gland Pharma Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹18,336 Mn (+23% YoY), PAT ₹2,908 Mn (+58%), adj. EBITDA margin 27%. US CDMO and launches lead; India and RoW weak.
Gland Pharma Results Update
Gland Pharma reported Q2FY27 revenue of Rs. 18,336 Mn, up 23% YoY, and PAT of Rs. 2,908 Mn, up 58% YoY. The press release accompanies its quarterly financial results filing.
Gland Pharma Q2 FY27 Results: Net Profit ₹290.8 Cr, Up 58.3% YoY
Gland Pharma Ltd reported revenue from operations of ₹1,834 Cr (+23.3% YoY) and net profit of ₹290.8 Cr (+58.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹290.8 Cr · +58.3% YoY
Gland Pharma Regulatory Approval
Gland Pharma received USFDA approval for Methylprednisolone Acetate Injectable Suspension USP in multiple vial formats. The product is bioequivalent to Pfizer's Depo-Medrol in a ~$214M US market.
Gland Pharma Management Change
Gland Pharma appointed Ajay Sahni as CEO of its wholly-owned subsidiary Gland Pharma International Pte. Ltd, effective 2 November 2026. He will lead the Cenexi business.